Immuno-Oncology | Specialty

Dr. Postow on the Current Treatment Landscape in Melanoma

September 8th 2016

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current treatment landscape in melanoma.

Dr. Stevenson on Potential of Immunotherapy in Squamous NSCLC

September 8th 2016

James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non–small cell lung cancer (NSCLC).

Expert Discusses Evolving Roles of Cabozantinib, Nivolumab in RCC

September 8th 2016

Jorge A. Garcia, MD, discusses the final survival data from the phase III METEOR trial, which was the basis for cabozantinib's (Cabometyx's) FDA approval, as well as the role the agent will now play along with nivolumab (Opdivo) in advanced RCC.

FDA Grants Pembrolizumab Priority Review in Frontline NSCLC

September 7th 2016

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab (Keytruda) as a first-line treatment for patients with PD-L1–positive non–small cell lung cancer.

Dr. McDermott on Major Findings of Efficacy and Safety of Nivolumab in RCC

September 7th 2016

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the findings of the phase III CheckMate-025 trial of nivolumab (Opdivo) versus everolimus (Afinitor) in renal cell carcinoma (RCC).

Prognostic Tool for Immuno Age Debuts

September 6th 2016

An assay that would evaluate the immune status of patients with colon cancer is poised to become the first of a series of Immunoscore tests for various tumor types.

Expert Discusses Next Steps With Immunotherapy in Melanoma

September 2nd 2016

Yvonee Saenger, MD, discusses ongoing developments with immunotherapy in melanoma.

Dr. Joshua M. Bauml on the Impact of Pembrolizumab in Head and Neck Cancer

September 2nd 2016

Dr. Rafii on Future Immunotherapy Approaches for Patients With Bladder Cancer

September 2nd 2016

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.

Atezolizumab Improves Survival in Phase III Lung Cancer Study

September 1st 2016

Atezolizumab (Tecentriq) improved survival compared with docetaxel in patients with advanced non–small cell lung cancer following the failure of platinum-based chemotherapy.

Dr. Barbara J. Gitlitz on Why PD-L1 is Not a Good Biomarker for Immunotherapy in Lung Cancer

September 1st 2016

Dr. Leora Horn on Toxicities With Immunotherapy in Lung Cancer

August 31st 2016

Dr. Giorgio Scagliotti on Taking a Targeted Approach to Immunotherapy in Lung Cancer

August 30th 2016

Dr. Nanus on Clinical Trials Exploring Immunotherapy in Bladder Cancer

August 29th 2016

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses ongoing clinical trials exploring immunotherapy agents for the treatment of patients with bladder cancer.

Expert Highlights Potential of Immunotherapy in Gastric Cancer

August 29th 2016

Zev Wainberg, MD, discusses a plethora of immunotherapy agents, such as pembrolizumab (Keytruda), durvalumab, avelumab, and apatinib, for the treatment of patients with gastric cancer, as well as a number of ongoing clinical trials in this space.

Dr. Poch on Nivolumab as a Treatment for Patients With Bladder Cancer

August 26th 2016

Michael A. Poch, MD, urologist and assistant member at Moffitt Cancer Center, discusses the potential of nivolumab (Opdivo) as a treatment for patients with metastatic bladder cancer.

Dr. Suresh S. Ramalingam on Optimizing Immunotherapies in Lung Cancer

August 26th 2016

Dr. Kelly on Immunotherapy Combinations for Patients With NSCLC

August 26th 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the potential of immunotherapy combinations as treatment for patients with non–small cell lung cancer (NSCLC).

Wolchok Discusses T-VEC, Other Immunotherapy Developments in Melanoma

August 25th 2016

Jedd D. Wolchok, MD, PhD, discusses two pivotal studies, their impacts, and how far the field of immunotherapy has come in melanoma.

Immunotherapy Advances Offer New Hope in Bladder Cancer

August 24th 2016

Michael Poch, MD, provides deeper insight into how immunotherapy has propelled the field of bladder cancer forward, as well as the research that still needs to be done.